Get started
OUTLOOK THERAPEUTICS INCOUTLOOK THERAPEUTICS INCOUTLOOK THERAPEUTICS INC

OUTLOOK THERAPEUTICS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

41O chart


Full chart

41O upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪69.10 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
1.26 EUR
Net income (FY)
‪−67.69 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪26.43 M‬
Beta (1Y)
0.76

Employees


Employees (FY)
23
Change (1Y)
−1 −4.17%
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪−2.94 M‬ EUR

About Outlook Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Robert Charles Jahr
Website
outlooktherapeutics.com
Headquarters
Iselin
Founded
2010
FIGI
BBG00NK8G7N1
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Check out other big names from the same industry as 41O.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

41O news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 41O is 1.68 EUR — it has increased by 4.88% in the past 24 hours. Watch OUTLOOK THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange OUTLOOK THERAPEUTICS INC stocks are traded under the ticker 41O.
41O stock has risen by 28.11% compared to the previous week, the month change is a 2.95% rise, over the last year OUTLOOK THERAPEUTICS INC has showed a −76.87% decrease.
We've gathered analysts' opinions on OUTLOOK THERAPEUTICS INC future price: according to them, 41O price has a max estimate of 18.46 EUR and a min estimate of 2.64 EUR. Watch 41O chart and read a more detailed OUTLOOK THERAPEUTICS INC stock forecast: see what analysts think of OUTLOOK THERAPEUTICS INC and suggest that you do with its stocks.
41O reached its all-time high on Mar 28, 2024 with the price of 11.66 EUR, and its all-time low was 0.86 EUR and was reached on Nov 27, 2024. View more price dynamics on 41O chart.
See other stocks reaching their highest and lowest prices.
41O stock is 6.31% volatile and has beta coefficient of 0.76. Track OUTLOOK THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is OUTLOOK THERAPEUTICS INC there?
Today OUTLOOK THERAPEUTICS INC has the market capitalization of ‪69.10 M‬, it has increased by 11.20% over the last week.
Yes, you can track OUTLOOK THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
OUTLOOK THERAPEUTICS INC is going to release the next earnings report on Aug 13, 2025. Keep track of upcoming events with our Earnings Calendar.
41O earnings for the last quarter are −0.37 EUR per share, whereas the estimation was −0.50 EUR resulting in a 26.31% surprise. The estimated earnings for the next quarter are −0.30 EUR per share. See more details about OUTLOOK THERAPEUTICS INC earnings.
OUTLOOK THERAPEUTICS INC revenue for the last quarter amounts to 0.00 EUR, despite the estimated figure of ‪580.72 K‬ EUR. In the next quarter, revenue is expected to reach ‪1.27 M‬ EUR.
41O net income for the last quarter is ‪−42.85 M‬ EUR, while the quarter before that showed ‪16.79 M‬ EUR of net income which accounts for −355.27% change. Track more OUTLOOK THERAPEUTICS INC financial stats to get the full picture.
No, 41O doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 9, 2025, the company has 23 employees. See our rating of the largest employees — is OUTLOOK THERAPEUTICS INC on this list?
Like other stocks, 41O shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OUTLOOK THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So OUTLOOK THERAPEUTICS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating OUTLOOK THERAPEUTICS INC stock shows the buy signal. See more of OUTLOOK THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.